Most labelling problems are not caught by the regulator. They are caught at goods-in, when a packer compares a delivered carton against the approved artwork and finds a missing excipient declaration, a superseded marketing authorisation holder address or a coding panel too small for the batch code.

By then the print run exists, the line is booked and someone has to decide whether to scrap or delay. This article is the checklist that avoids that conversation. It covers the UK pharmaceutical labelling requirements for outer packaging and immediate containers, what may be left off blisters and small packs, what Braille and leaflet accessibility demand, and what a packer verifies before and during a run.

Two things sit deliberately outside it: the licensing framework and current serialisation position, covered in our article on pharmaceutical packaging regulations in the UK, and how the particulars should be laid out so the pack reads safely, covered in our article on pharmaceutical packaging design and regulatory best practice.

The legal basis for UK pharmaceutical labelling requirements

Part 13 of the Human Medicines Regulations 2012 sets the statutory requirements for packaging, labelling and the patient information leaflet for medicines placed on the UK market. The particulars must match the marketing authorisation, so a label change and a variation are the same project seen from two directions. Plan the artwork revision, the component lead time and the changeover point in the packing schedule together, and decide in advance whether existing stock may be run through.

Everything below assumes a licensed operation: packing, labelling or rework of a licensed medicine requires an MHRA MIA and QP certification.

Statutory particulars on the outer packaging

The outer packaging of a UK medicine must carry:

• The name of the medicine, followed by strength and pharmaceutical form, and where relevant whether it is for babies, children or adults.
• The active substances expressed qualitatively and quantitatively by common name, per dose unit or per unit of volume or weight.
• Excipients requiring declaration, with a full excipient list for injectables, topical preparations and eye preparations.
• The pharmaceutical form and the contents by weight, volume or number of dose units.
• The method of administration and, where necessary, the route.
• The warning "Keep out of the sight and reach of children".
• Any special warning necessary for that medicine.
• The expiry date, expressed clearly as month and year.
• Special storage precautions, and precautions for disposal of unused product or waste, where applicable.
• The name and address of the marketing authorisation holder.
• The marketing authorisation number.
• The manufacturer's batch number.
• For products sold without prescription, instructions for use.

Legibility matters as much as presence. Particulars must be easily legible, clearly comprehensible and indelible, and in English. Other languages may appear provided the same particulars appear in all of them.

One further particular applies to every UK pack: "UK Only" in a minimum 7-point font, which may sit anywhere on the outer packaging. Because joint EU/UK packs have not been permitted since 1 January 2025, it belongs on a UK-specific carton with its own artwork version.

Reduced particulars for blisters and small immediate packaging

Two relaxations exist and both are frequently misapplied.

Blister strips enclosed in an outer carrying the full particulars need only the name of the medicine, the name of the marketing authorisation holder, the expiry date and the batch number.

Small immediate packaging where the full particulars cannot reasonably fit, typically small ampoules and vials, needs the name of the medicine with strength and route where appropriate, the method of administration, the batch number, the expiry date and the contents.

The exemption applies to the immediate container inside a compliant outer, not to a pack sold as it stands. If the blister is the outer, the blister carries everything. The common failure is a decision taken once for one presentation and inherited by a later one that no longer has the outer the exemption assumed.

Where the immediate container is a vial, ampoule or metered dose inhaler, the particulars usually arrive as a printed label, which makes label material, adhesive, curvature and application accuracy part of the compliance question.

Printed, not over-labelled

Information required by Part 13 must be printed directly onto the packaging. Over-labelling is not a compliance route for standard UK market packs, and a label applied over incorrect printed text will not satisfy an inspector.

That does not make labelling equipment irrelevant. Labelling remains essential for vials, ampoules, MDIs and other sterile-filled units, for export packs, and for authorised rework under change control. The distinction is between labelling as the designed presentation and over-labelling as a repair for an artwork error.

Braille and accessible information

The name of the medicine must appear in Braille on the outer packaging of medicines intended for patient use, using Unified English Braille. Placement needs early thought. The dots have to sit on a flat panel clear of glue flaps, crease lines and any coding or serialisation panel, and must not cross a tuck or a perforation. Embossing also changes carton stiffness in ways that affect erecting and closing, so trial the pack rather than assume it.

Dot height is the parameter that degrades. It is checked at proofing and can be flattened if a carton stack is compressed in transit or stored under load. Where a range carries more than one strength, confirm the Braille distinguishes them; a name-only emboss across three strengths gives a blind patient nothing to select on.

The patient information leaflet must reflect the approved product information, be legible and comprehensible, and be available in formats accessible to blind and partially sighted patients on request from the marketing authorisation holder. Leaflet fold, insertion orientation and the space it occupies inside the carton are packing considerations as much as regulatory ones. A leaflet one fold too thick will slow a line or jam it.

What the packer checks at goods-in and on line

At goods-in, printed components are checked against the approved artwork at the correct version: text, colours against the agreed standard, Braille presence and legibility, varnish-free coding panels, and dimensions against the machine specification. Components stay quarantined until released. A component that fails here is an inconvenience; the same fault found mid-run is a deviation.

On line, the checks differ. Line clearance confirms that no components from the previous job remain. Batch coding and expiry date are verified at start-up, at intervals and at end of run, with samples retained. Leaflet presence, leaflet version and blister count are confirmed. Where an anti-tamper device or a 2D code is applied for export, print quality and code readability are verified against specification. Reconciliation closes the batch: quantities issued, used, sampled, destroyed and returned must add up.

Key takeaways

• Part 13 of the Human Medicines Regulations 2012 sets the statutory particulars for UK packs, and every particular must match the marketing authorisation.
• Reduced particulars apply only to blisters inside a compliant outer and to small immediate packaging, never to a pack sold as it stands.
• "UK Only" is required at a minimum of 7-point, and joint EU/UK packs have not been permitted since 1 January 2025.
• Statutory information must be printed directly onto the pack; over-labelling suits sterile-filled units, export packs and authorised rework, not an artwork error.
• The medicine name must appear in Unified English Braille on patient-use outer packaging, clear of flaps, creases and coding panels, with dot height verified at proofing.

Meeting UK labelling requirements with Central Pharma

Central Pharma has been a contract filler and packer since 2006, working from a 267,000 sq ft licensed site in Bedford under an MHRA MIA and WDA(H), with three Qualified Persons and QP release to more than 60 countries. We check artwork against the statutory particulars and against what the line can physically run, control versions through to QA sign-off, label vials, ampoules, MDIs and other sterile-filled units, and carry the goods-in, line clearance and reconciliation checks above. Contact us to discuss a labelling or repack project.

To stay informed on our latest thinking and technology developments, follow us on LinkedIn.

Contact Us Today

View all news